Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 14/20 | 0.66 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atigliflozin SCHEMBL14981898 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL874745 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL15628877 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL873867 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL13641405 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL14985137 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL13644156 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL14648453 | 0.91 | SLC5A2 (0.55) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL13255024 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL13088388 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1ACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152159-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20170239281-A1 | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239281-A1 | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS | SLC5A2, SLC5A1, SLC6A3 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4733/4885 |
| US-20220152159-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ACHE 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.